YOLFTbeta
Klaria Pharma Holding AB

Klaria Pharma Holding AB

KLAR · ST · Healthcare / Drug Manufacturers - Specialty & Generic

0.502SEK+0.01 (+2.03%)

Price History

Full chart

Market Stats

Previous Close0.492
Open0.4855
Day Range0.478 – 0.502
52-Week Range0.45 – 1.33
Volume207.28K
Market Cap145.37M
P/E (TTM)0.00
Forward P/E1.95
EPS-0.19
Dividend Yield0.00%
Beta1.20
50-Day Avg0.7785
200-Day Avg0.8426

About

Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction. The company also offers Sirolimus which is in pre-clinical stage for prevention of organ transplant rejection. In addition, it is involved in commercialization and sale of cannabis/cannabinoids. Klaria Pharma Holding AB (publ.) was incorporated in 2014 and is based in Uppsala, Sweden.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEODr. Scott Boyer
  • Employees4
  • HeadquartersVirdings Allé 2, Uppsala, Sweden, 754 50, Sweden
  • Websitehttps://www.klaria.com

Leadership

  • Dr. Scott BoyerCEO & Director · b. 1962
  • Mr. Hans RichterChief Financial Officer · b. 1949
  • Mr. Marc Willuhn Ph.D.Head of Chemistry, Manufacturing & Control · b. 1969

Financials

Income Statement

Currency: SEK2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--02.27M649.00K4.22M7.22M6.11M5.87M8.45M2.25M9.00M
Growth (%)-----71.47%+550.69%+70.97%-15.35%-3.99%+44.07%-73.41%+300.36%
Cost of Revenue301.07K-9.00K-9.58M-13.43M10.96M-9.00K-11.22M
Gross Profit-301.07K--9.00K2.27M-8.93M4.22M-6.21M-4.85M5.87M8.45M2.25M-2.23M
Gross Margin---100.00%-1375.96%100.00%-86.04%-79.40%100.00%100.00%100.00%-24.82%
Operating Expense301.07K-14.47M24.10M18.36M25.32M42.53M45.26M60.84M40.30M33.45M18.18M
Operating Income-602.14K-5.59M-14.47M-21.82M-27.29M-21.09M-48.74M-50.11M-54.97M-31.85M-31.21M-20.42M
Operating Margin----959.34%-4205.39%-499.46%-675.04%-819.85%-936.84%-376.73%-1388.21%-226.87%
EBITDA-602.14K-5.59M-14.54M-11.99M-17.73M-11.06M-35.41M-39.41M-44.80M-20.81M-19.99M-9.20M
EBITDA Margin----526.86%-2731.43%-261.83%-490.51%-644.86%-763.41%-246.18%-889.15%-102.21%
Net Income--5.59M-14.55M-21.57M-27.31M-22.49M-51.44M-53.53M-63.77M-35.78M-47.75M-38.90M
Net Income Margin----948.04%-4207.40%-532.61%-712.45%-875.88%-1086.81%-423.28%-2124.11%-432.22%
R&D-2.85M9.99M9.50M22.34M16.86M41.22M63.49M51.36M24.95M22.11M20.10M
R&D as % of Total Revenue---417.49%3442.06%399.31%570.94%1038.78%875.19%295.08%983.32%223.33%
Interest Expense-1.00K72.00K6.00K2.00K1.35M2.56M3.17M7.84M3.68M16.42M13.66M
Interest Expense % of Total Revenue---0.26%0.31%31.99%35.50%51.80%133.66%43.54%730.34%151.82%

Balance Sheet

Currency: SEK2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets50.00K176.88M162.03M155.87M106.25M101.73M132.41M118.31M120.27M72.95M57.27M40.77M
Total Liabilities502.69K2.29M1.99M2.35M11.55M19.62M22.81M48.89M44.19M31.81M53.96M44.65M
Total Equity50.00K174.59M160.04M153.52M94.70M82.11M109.59M69.41M76.08M41.13M3.31M-3.88M
Cash491.63K45.63M31.10M17.10M7.96M2.92M31.25M25.49M16.76M1.25M598.00K342.00K
Total Debt-----10.77M10.26M31.72M17.09M18.93M23.07M-
Net Debt-491.63K-45.63M-31.10M-17.10M-7.96M7.85M-20.99M6.23M324.00K17.68M22.47M-342.00K

Cash Flow

Currency: SEK2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-4.43M-14.39M-12.06M-9.13M-14.80M-35.30M-24.80M-49.73M-9.06M-11.94M-35.04M
Investing Cash Flow-69.00K-65.00K-2.70M387.00K-387.00K13.05M-42.00K-42.00K000
Financing Cash Flow50.13M-75.00K756.00K-13.00K9.37M50.56M19.04M41.06M-6.46M11.27M34.78M
Capital Expenditure065.00K65.00K33.00K33.00K33.00K42.00K42.00K0035.04M
Free Cash Flow-4.43M-14.46M-12.13M-9.13M-14.80M-35.33M-24.80M-49.77M-3.37M-11.94M-35.04M
FCF to OCF100.00%100.45%100.54%100.00%100.00%100.09%100.00%100.08%37.17%100.00%100.00%

Earnings

Report DateMar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Aug 28, 2020Nov 26, 2020Jan 29, 2021May 21, 2021Sep 1, 2021Dec 1, 2021Feb 10, 2022May 12, 2022Aug 26, 2022Nov 18, 2022Feb 10, 2023May 12, 2023Aug 25, 2023Nov 24, 2023Mar 1, 2024May 16, 2024Aug 22, 2024Nov 21, 2024Feb 28, 2025May 21, 2025Aug 28, 2025Nov 27, 2025Feb 23, 2026May 29, 2026Aug 31, 2026
EPS Estimate------------------------------------------
EPS Actual-0.12-0.14-0.10-0.09-0.10-0.10-0.04-0.12-0.11-0.13-0.11-0.45-0.06-0.23-0.21-0.15-0.29-0.24-0.28-0.340.32-0.28-0.27-0.71-0.35-0.23-0.26-0.22-0.06-0.09-0.10-0.09-0.11-0.11-0.06-0.11-0.01-0.14-0.04-0.07-0.04-0.05
Surprise------------------------------------------
Timing-----------------------Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-After-hoursPre-marketPre-marketPre-marketPre-market-----

Key Statistics & Ratios

Market Cap145.37M
Enterprise Value171.75M
Trailing P/E0.00
Forward P/E1.95
Price / Sales1453.72
Price / Book40.37
EPS-0.19
Book Value-0.137
Revenue (TTM)100.00K
Gross Profit (TTM)100.00K
EBITDA-28.72M
Profit Margin0.00%
Operating Margin-107530.00%
Return on Equity-527.01%
Return on Assets-56.79%
Shares Outstanding245.98M
Shares Float241.34M
Beta1.20
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%